Floatz logo

ONATASERTIB

Safety and Pharmacokinetics in Healthy Volunteer Subjects

CelgeneSmall moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Safety and Pharmacokinetics in Healthy Volunteer Subjects cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

ONATASERTIB is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical CancerDormant
CC
Indicative ·
45 / 100
View asset →
carcinoid tumorDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →